{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:52:49Z","timestamp":1787165569479,"version":"build-2736575974"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88887.310463\/2018-00"],"award-info":[{"award-number":["88887.310463\/2018-00"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88887.310463\/2018-00"],"award-info":[{"award-number":["88887.310463\/2018-00"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Region of Southern Denmark Research Fund","award":["J.nr.: 20\/14277, Efond 519"],"award-info":[{"award-number":["J.nr.: 20\/14277, Efond 519"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Serous ovarian carcinoma is the most frequent histological subgroup of ovarian cancer and the leading cause of death among gynecologic tumors. The tumor microenvironment and cancer-associated fibroblasts (CAFs) have a critical role in the origin and progression of cancer. We comprehensively characterized the crosstalk between CAFs and ovarian cancer cells from malignant fluids to identify specific ligands and receptors mediating intercellular communications and disrupted pathways related to prognosis and therapy response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Malignant fluids of serous ovarian cancer, including tumor-derived organoids, CAFs-enriched (eCAFs), and malignant effusion cells (no cultured) paired with normal ovarian tissues, were explored by RNA-sequencing. These data were integrated with single-cell RNA-sequencing data of ascites from ovarian cancer patients. The most relevant ligand and receptor interactions were used to identify differentially expressed genes with prognostic values in ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CAF ligands and epithelial cancer cell receptors were enriched for PI3K-AKT, focal adhesion, and epithelial-mesenchymal transition signaling pathways. Collagens, MIF, MDK, APP, and laminin were detected as the most significant signaling, and the top ligand-receptor interactions THBS2\/THBS3 (CAFs)\u2014CD47 (cancer cells), MDK (CAFs)\u2014NCL\/SDC2\/SDC4 (cancer cells) as potential therapeutic targets. Interestingly, 34 genes encoding receptors and ligands of the PI3K pathway were associated with the outcome, response to treatment, and overall survival in ovarian cancer. Up-regulated genes from this list consistently predicted a worse overall survival (hazard ratio\u2009&gt;\u20091.0 and log-rank\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) in two independent validation cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study describes critical signaling pathways, ligands, and receptors involved in the communication between CAFs and cancer cells that have prognostic and therapeutic significance in ovarian cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12964-022-00991-4","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T17:02:54Z","timestamp":1668013374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Single-cell and bulk RNA sequencing reveal ligands and receptors associated with worse overall survival in serous ovarian cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Robson Francisco","family":"Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Matos","family":"do Canto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie","family":"Abildgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Malik","family":"Aagaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica S\u00f8gaard","family":"Tronhjem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Waldstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Henrik","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina Dahl","family":"Steffensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Regina","family":"Rogatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"issue":"3","key":"991_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA A Cancer J Clin"},{"key":"991_CR2","unstructured":"Kurman RJ, International agency for research on cancer, world health organization, eds. WHO classification of tumours of female reproductive organs. 4th ed. International agency for research on cancer; 2014."},{"issue":"2","key":"991_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/01.AOG.0000227787.24587.d1","volume":"108","author":"DM Gershenson","year":"2006","unstructured":"Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108(2):361\u20138. https:\/\/doi.org\/10.1097\/01.AOG.0000227787.24587.d1.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"991_CR4","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft gynaekologische onkologie studiengruppe ovarialkarzinom (AGO-OVAR) and the groupe d\u2019investigateurs nationaux pour les etudes des cancers de l\u2019Ovaire (GINECO). Cancer. 2009;115(6):1234\u201344. https:\/\/doi.org\/10.1002\/cncr.24149.","journal-title":"Cancer"},{"issue":"1","key":"991_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13048-019-0484-6","volume":"12","author":"A Gadducci","year":"2019","unstructured":"Gadducci A, Guarneri V, Peccatori FA, et al. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J Ovarian Res. 2019;12(1):9. https:\/\/doi.org\/10.1186\/s13048-019-0484-6.","journal-title":"J Ovarian Res"},{"issue":"10","key":"991_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943\u201353. https:\/\/doi.org\/10.1056\/NEJMoa0908806.","journal-title":"N Engl J Med"},{"issue":"10177","key":"991_CR7","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. The Lancet. 2019;393(10177):1240\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(18)32552-2.","journal-title":"The Lancet"},{"issue":"4","key":"991_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DSP, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13(4):273\u201382. https:\/\/doi.org\/10.1038\/nrc3432.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"991_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00404-014-3364-8","volume":"290","author":"F Zeppernick","year":"2014","unstructured":"Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet. 2014;290(5):839\u201342. https:\/\/doi.org\/10.1007\/s00404-014-3364-8.","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"991_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nrc1611","volume":"5","author":"H Naora","year":"2005","unstructured":"Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005;5(5):355\u201366. https:\/\/doi.org\/10.1038\/nrc1611.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"991_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer. 2020;123(1):9\u201316. https:\/\/doi.org\/10.1038\/s41416-020-0875-x.","journal-title":"Br J Cancer"},{"issue":"25","key":"991_CR12","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1038\/onc.2016.509","volume":"36","author":"TS Lau","year":"2017","unstructured":"Lau TS, Chan LKY, Wong ECH, et al. A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNF\u03b1-TGF\u03b1-EGFR. Oncogene. 2017;36(25):3576\u201387. https:\/\/doi.org\/10.1038\/onc.2016.509.","journal-title":"Oncogene"},{"issue":"12","key":"991_CR13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18(12):792\u2013804. https:\/\/doi.org\/10.1038\/s41571-021-00546-5.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"991_CR14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386. https:\/\/doi.org\/10.1038\/s41568-019-0238-1.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"991_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nrc.2017.58","volume":"17","author":"T Baslan","year":"2017","unstructured":"Baslan T, Hicks J. Unravelling biology and shifting paradigms in cancer with single-cell sequencing. Nat Rev Cancer. 2017;17(9):557\u201369. https:\/\/doi.org\/10.1038\/nrc.2017.58.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"991_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-020-00292-x","volume":"22","author":"E Armingol","year":"2021","unstructured":"Armingol E, Officer A, Harismendy O, Lewis NE. Deciphering cell\u2013cell interactions and communication from gene expression. Nat Rev Genet. 2021;22(2):71\u201388. https:\/\/doi.org\/10.1038\/s41576-020-00292-x.","journal-title":"Nat Rev Genet"},{"issue":"8","key":"991_CR17","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","volume":"26","author":"B Izar","year":"2020","unstructured":"Izar B, Tirosh I, Stover EH, et al. A single-cell landscape of high-grade serous ovarian cancer. Nat Med. 2020;26(8):1271\u20139. https:\/\/doi.org\/10.1038\/s41591-020-0926-0.","journal-title":"Nat Med"},{"issue":"11","key":"991_CR18","doi-asserted-by":"publisher","first-page":"e0206785","DOI":"10.1371\/journal.pone.0206785","volume":"13","author":"AJ Shih","year":"2018","unstructured":"Shih AJ, Menzin A, Whyte J, et al. Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq. PLoS ONE. 2018;13(11):e0206785. https:\/\/doi.org\/10.1371\/journal.pone.0206785.","journal-title":"PLoS ONE"},{"issue":"2","key":"991_CR19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ccell.2020.01.003","volume":"37","author":"Z Hu","year":"2020","unstructured":"Hu Z, Artibani M, Alsaadi A, et al. The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. Cancer Cell. 2020;37(2):226-242.e7. https:\/\/doi.org\/10.1016\/j.ccell.2020.01.003.","journal-title":"Cancer Cell"},{"issue":"3","key":"991_CR20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ygyno.2017.01.015","volume":"144","author":"BJ Winterhoff","year":"2017","unstructured":"Winterhoff BJ, Maile M, Mitra AK, et al. Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells. Gynecol Oncol. 2017;144(3):598\u2013606. https:\/\/doi.org\/10.1016\/j.ygyno.2017.01.015.","journal-title":"Gynecol Oncol"},{"issue":"21","key":"991_CR21","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1038\/s41388-020-1288-2","volume":"39","author":"T Kan","year":"2020","unstructured":"Kan T, Wang W, Ip PP, et al. Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites. Oncogene. 2020;39(21):4227\u201340. https:\/\/doi.org\/10.1038\/s41388-020-1288-2.","journal-title":"Oncogene"},{"issue":"1","key":"991_CR22","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1038\/s41467-021-24009-8","volume":"12","author":"EA Pietil\u00e4","year":"2021","unstructured":"Pietil\u00e4 EA, Gonzalez-Molina J, Moyano-Galceran L, et al. Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance. Nat Commun. 2021;12(1):3904. https:\/\/doi.org\/10.1038\/s41467-021-24009-8.","journal-title":"Nat Commun"},{"issue":"19","key":"991_CR23","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","volume":"32","author":"P Ewels","year":"2016","unstructured":"Ewels P, Magnusson M, Lundin S, K\u00e4ller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016;32(19):3047\u20138. https:\/\/doi.org\/10.1093\/bioinformatics\/btw354.","journal-title":"Bioinformatics"},{"key":"991_CR24","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.12688\/f1000research.15931.2","volume":"7","author":"SW Wingett","year":"2018","unstructured":"Wingett SW, Andrews S. FastQ screen: a tool for multi-genome mapping and quality control. F1000Res. 2018;7:1338. https:\/\/doi.org\/10.12688\/f1000research.15931.2.","journal-title":"F1000Res"},{"issue":"1","key":"991_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635.","journal-title":"Bioinformatics"},{"issue":"2","key":"991_CR26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W. HTSeq\u2013a python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31(2):166\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/btu638.","journal-title":"Bioinformatics"},{"issue":"W1","key":"991_CR27","doi-asserted-by":"publisher","first-page":"W537","DOI":"10.1093\/nar\/gky379","volume":"46","author":"E Afgan","year":"2018","unstructured":"Afgan E, Baker D, Batut B, et al. The galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res. 2018;46(W1):W537\u201344. https:\/\/doi.org\/10.1093\/nar\/gky379.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"991_CR28","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/bioinformatics\/btt772","volume":"30","author":"J Starru\u00df","year":"2014","unstructured":"Starru\u00df J, de Back W, Brusch L, Deutsch A. Morpheus: a user-friendly modeling environment for multiscale and multicellular systems biology. Bioinformatics. 2014;30(9):1331\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btt772.","journal-title":"Bioinformatics"},{"issue":"12","key":"991_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8.","journal-title":"Genome Biol"},{"issue":"W1","key":"991_CR30","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90-97. https:\/\/doi.org\/10.1093\/nar\/gkw377.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"991_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 2013;14(1):128. https:\/\/doi.org\/10.1186\/1471-2105-14-128.","journal-title":"BMC Bioinform"},{"issue":"3","key":"991_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie Z, Bailey A, Kuleshov MV, et al. Gene set knowledge discovery with enrichr. Curr Protoc. 2021;1(3):90.","journal-title":"Curr Protoc"},{"issue":"1","key":"991_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar R. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207\u201310. https:\/\/doi.org\/10.1093\/nar\/30.1.207.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"991_CR34","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart T, Butler A, Hoffman P, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888-1902.e21. https:\/\/doi.org\/10.1016\/j.cell.2019.05.031.","journal-title":"Cell"},{"issue":"1","key":"991_CR35","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, et al. Inference and analysis of cell-cell communication using cell chat. Nat Commun. 2021;12(1):1088. https:\/\/doi.org\/10.1038\/s41467-021-21246-9.","journal-title":"Nat Commun"},{"issue":"6","key":"991_CR36","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675\u20138. https:\/\/doi.org\/10.1038\/s41587-020-0546-8.","journal-title":"Nat Biotechnol"},{"key":"991_CR37","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1016\/j.csbj.2021.07.014","volume":"19","author":"B Gy\u0151rffy","year":"2021","unstructured":"Gy\u0151rffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101\u20139. https:\/\/doi.org\/10.1016\/j.csbj.2021.07.014.","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"991_CR38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/1471-2105-12-474","volume":"12","author":"Q Li","year":"2011","unstructured":"Li Q, Birkbak NJ, Gyorffy B, Szallasi Z, Eklund AC. Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinform. 2011;12(1):474. https:\/\/doi.org\/10.1186\/1471-2105-12-474.","journal-title":"BMC Bioinform"},{"issue":"1","key":"991_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat J. FIGO committee on gynecologic oncology staging classification for cancer of the ovary fallopian tube and peritoneum. Int J Gynecol Obstet. 2014;124(1):1\u20135. https:\/\/doi.org\/10.1016\/j.ijgo.2013.10.001.","journal-title":"Int J Gynecol Obstet"},{"issue":"4","key":"991_CR40","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.stemcr.2020.03.004","volume":"14","author":"N Maenhoudt","year":"2020","unstructured":"Maenhoudt N, Defraye C, Boretto M, et al. Developing organoids from ovarian cancer as experimental and preclinical models. Stem Cell Reports. 2020;14(4):717\u201329. https:\/\/doi.org\/10.1016\/j.stemcr.2020.03.004.","journal-title":"Stem Cell Reports"},{"issue":"1","key":"991_CR41","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12935-020-01344-2","volume":"20","author":"T Zhu","year":"2020","unstructured":"Zhu T, Chen R, Wang J, Yue H, Lu X, Li J. The prognostic value of ITGA and ITGB superfamily members in patients with high grade serous ovarian cancer. Cancer Cell Int. 2020;20(1):257. https:\/\/doi.org\/10.1186\/s12935-020-01344-2.","journal-title":"Cancer Cell Int"},{"key":"991_CR42","doi-asserted-by":"publisher","first-page":"1609855","DOI":"10.3389\/pore.2021.1609855","volume":"27","author":"B Diao","year":"2021","unstructured":"Diao B, Yang P. Comprehensive analysis of the expression and prognosis for laminin genes in ovarian cancer. Pathol Oncol Res. 2021;27:1609855. https:\/\/doi.org\/10.3389\/pore.2021.1609855.","journal-title":"Pathol Oncol Res"},{"issue":"5","key":"991_CR43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4161\/cbt.10.5.12585","volume":"10","author":"C Cole","year":"2010","unstructured":"Cole C, Lau S, Backen A, et al. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther. 2010;10(5):495\u2013504. https:\/\/doi.org\/10.4161\/cbt.10.5.12585.","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"991_CR44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13073-021-00922-x","volume":"13","author":"S Olbrecht","year":"2021","unstructured":"Olbrecht S, Busschaert P, Qian J, et al. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. Genome Med. 2021;13(1):111. https:\/\/doi.org\/10.1186\/s13073-021-00922-x.","journal-title":"Genome Med"},{"key":"991_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.576565","volume":"10","author":"F Yang","year":"2021","unstructured":"Yang F, Zhao Z, Cai S, et al. Detailed molecular mechanism and potential drugs for COL1A1 in carboplatin-resistant ovarian cancer. Front Oncol. 2021;10: 576565. https:\/\/doi.org\/10.3389\/fonc.2020.576565.","journal-title":"Front Oncol"},{"issue":"2","key":"991_CR46","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3892\/or.2015.4048","volume":"34","author":"Y Dong","year":"2015","unstructured":"Dong Y, Li J, Han F, et al. High IGF2 expression is associated with poor clinical outcome in human ovarian cancer. Oncol Rep. 2015;34(2):936\u201342. https:\/\/doi.org\/10.3892\/or.2015.4048.","journal-title":"Oncol Rep"},{"key":"991_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00306-8","author":"Y Bai","year":"2021","unstructured":"Bai Y, Ren C, Wang B, et al. LncRNA MAFG-AS1 promotes the malignant phenotype of ovarian cancer by upregulating NFKB1-dependent IGF1. Cancer Gene Ther. 2021. https:\/\/doi.org\/10.1038\/s41417-021-00306-8.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"991_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1757-2215-5-35","volume":"5","author":"S Fujiwara","year":"2012","unstructured":"Fujiwara S, Terai Y, Kawaguchi H, et al. GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer. J Ovarian Res. 2012;5(1):35. https:\/\/doi.org\/10.1186\/1757-2215-5-35.","journal-title":"J Ovarian Res"},{"key":"991_CR49","doi-asserted-by":"publisher","unstructured":"Wang K, Li D, Sun L. High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancer. 2016: https:\/\/doi.org\/10.2147\/OTT.S96309","DOI":"10.2147\/OTT.S96309"},{"issue":"8","key":"991_CR50","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/ijc.32854","volume":"146","author":"M Yoshihara","year":"2020","unstructured":"Yoshihara M, Kajiyama H, Yokoi A, et al. Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1\/Akt signaling pathway. Int J Cancer. 2020;146(8):2268\u201380. https:\/\/doi.org\/10.1002\/ijc.32854.","journal-title":"Int J Cancer"},{"key":"991_CR51","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.omto.2019.12.002","volume":"16","author":"H Liang","year":"2020","unstructured":"Liang H, Yu M, Yang R, et al. A PTAL-miR-101-FN1 axis promotes EMT and invasion-metastasis in serous ovarian cancer. Molecul Ther Oncolytic. 2020;16:53\u201362. https:\/\/doi.org\/10.1016\/j.omto.2019.12.002.","journal-title":"Molecul Ther Oncolytic"},{"key":"991_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/5561651","volume":"2021","author":"H Bao","year":"2021","unstructured":"Bao H, Huo Q, Yuan Q, Xu C. Fibronectin 1: a potential biomarker for ovarian cancer. Dis Mark. 2021;2021:1\u201311. https:\/\/doi.org\/10.1155\/2021\/5561651.","journal-title":"Dis Mark"},{"issue":"15","key":"991_CR53","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1158\/1078-0432.CCR-03-0589","volume":"10","author":"PH Thaker","year":"2004","unstructured":"Thaker PH, Deavers M, Celestino J, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 2004;10(15):5145\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0589.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"991_CR54","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1007\/s13277-014-1923-z","volume":"35","author":"T Didem","year":"2014","unstructured":"Didem T, Faruk T, Senem K, et al. Clinical significance of serum tenascin-c levels in epithelial ovarian cancer. Tumor Biol. 2014;35(7):6777\u201382. https:\/\/doi.org\/10.1007\/s13277-014-1923-z.","journal-title":"Tumor Biol"},{"key":"991_CR55","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3389\/fgene.2019.01031","volume":"10","author":"J Liu","year":"2019","unstructured":"Liu J, Meng H, Li S, et al. Identification of potential biomarkers in association with progression and prognosis in epithelial ovarian cancer by integrated bioinformatics analysis. Front Genet. 2019;10:1031. https:\/\/doi.org\/10.3389\/fgene.2019.01031.","journal-title":"Front Genet"},{"issue":"32","key":"991_CR56","doi-asserted-by":"publisher","first-page":"53432","DOI":"10.18632\/oncotarget.18515","volume":"8","author":"PY Chang","year":"2017","unstructured":"Chang PY, Liao YP, Wang HC, et al. An epigenetic signature of adhesion molecules predicts poor prognosis of ovarian cancer patients. Oncotarget. 2017;8(32):53432\u201349. https:\/\/doi.org\/10.18632\/oncotarget.18515.","journal-title":"Oncotarget"},{"issue":"1","key":"991_CR57","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","volume":"6","author":"F Wu","year":"2021","unstructured":"Wu F, Yang J, Liu J, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Sig Transduct Target Ther. 2021;6(1):218. https:\/\/doi.org\/10.1038\/s41392-021-00641-0.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"991_CR58","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41467-018-03348-z","volume":"9","author":"AM Givel","year":"2018","unstructured":"Givel AM, Kieffer Y, Scholer-Dahirel A, et al. miR200-regulated CXCL12\u03b2 promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat Commun. 2018;9(1):1056. https:\/\/doi.org\/10.1038\/s41467-018-03348-z.","journal-title":"Nat Commun"},{"issue":"8","key":"991_CR59","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191094","volume":"217","author":"A Hussain","year":"2020","unstructured":"Hussain A, Voisin V, Poon S, et al. Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21. J Exp Med. 2020;217(8): e20191094. https:\/\/doi.org\/10.1084\/jem.20191094.","journal-title":"J Exp Med"},{"issue":"26","key":"991_CR60","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1038\/s41388-021-01865-8","volume":"40","author":"YH Wu","year":"2021","unstructured":"Wu YH, Huang YF, Chang TH, et al. COL11A1 activates cancer-associated fibroblasts by modulating TGF-\u03b23 through the NF-\u03baB\/IGFBP2 axis in ovarian cancer cells. Oncogene. 2021;40(26):4503\u201319. https:\/\/doi.org\/10.1038\/s41388-021-01865-8.","journal-title":"Oncogene"},{"issue":"16","key":"991_CR61","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1158\/0008-5472.CAN-13-0023","volume":"73","author":"TL Yeung","year":"2013","unstructured":"Yeung TL, Leung CS, Wong KK, et al. TGF-\u03b2 modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 2013;73(16):5016\u201328. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0023.","journal-title":"Cancer Res"},{"issue":"1","key":"991_CR62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/carcin\/bgr230","volume":"33","author":"J Cai","year":"2012","unstructured":"Cai J, Tang H, Xu L, et al. Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis. 2012;33(1):20\u20139. https:\/\/doi.org\/10.1093\/carcin\/bgr230.","journal-title":"Carcinogenesis"},{"issue":"11","key":"991_CR63","doi-asserted-by":"publisher","first-page":"E406","DOI":"10.3390\/cancers10110406","volume":"10","author":"S Dasari","year":"2018","unstructured":"Dasari S, Fang Y, Mitra AK. Cancer associated fibroblasts: naughty neighbors that drive ovarian cancer progression. Cancers (Basel). 2018;10(11):E406. https:\/\/doi.org\/10.3390\/cancers10110406.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"991_CR64","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1158\/1535-7163.MCT-07-0118","volume":"6","author":"T Hagemann","year":"2007","unstructured":"Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther. 2007;6(7):1993\u20132002. https:\/\/doi.org\/10.1158\/1535-7163.MCT-07-0118.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"991_CR65","first-page":"5233","volume":"32","author":"M Krockenberger","year":"2012","unstructured":"Krockenberger M, Kranke P, H\u00e4usler S, et al. Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis. Anticancer Res. 2012;32(12):5233\u20138.","journal-title":"Anticancer Res"},{"issue":"5","key":"991_CR66","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41585-019-0171-9","volume":"16","author":"JC Penticuff","year":"2019","unstructured":"Penticuff JC, Woolbright BL, Sielecki TM, Weir SJ, Taylor JA. MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential. Nat Rev Urol. 2019;16(5):318\u201328. https:\/\/doi.org\/10.1038\/s41585-019-0171-9.","journal-title":"Nat Rev Urol"},{"issue":"10","key":"991_CR67","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1038\/s41388-019-1124-8","volume":"39","author":"PS Filippou","year":"2020","unstructured":"Filippou PS, Karagiannis GS, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene. 2020;39(10):2040\u201354. https:\/\/doi.org\/10.1038\/s41388-019-1124-8.","journal-title":"Oncogene"},{"issue":"2","key":"991_CR68","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ygyno.2016.08.325","volume":"143","author":"RM Brightwell","year":"2016","unstructured":"Brightwell RM, Grzankowski KS, Lele S, et al. The CD47 \u201cdon\u2019t eat me signal\u201d is highly expressed in human ovarian cancer. Gynecol Oncol. 2016;143(2):393\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2016.08.325.","journal-title":"Gynecol Oncol"},{"key":"991_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109105","volume":"119","author":"CL Wang","year":"2019","unstructured":"Wang CL, Lin MJ, Hsu CY, et al. CD47 promotes cell growth and motility in epithelial ovarian cancer. Biomed Pharmacother. 2019;119: 109105. https:\/\/doi.org\/10.1016\/j.biopha.2019.109105.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"991_CR70","first-page":"2901","volume":"9","author":"Y Li","year":"2017","unstructured":"Li Y, Lu S, Xu Y, et al. Overexpression of CD47 predicts poor prognosis and promotes cancer cell invasion in high-grade serous ovarian carcinoma. Am J Transl Res. 2017;9(6):2901\u201310.","journal-title":"Am J Transl Res"},{"issue":"9","key":"991_CR71","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/1541-7786.MCR-20-0956","volume":"19","author":"A Shimizu","year":"2021","unstructured":"Shimizu A, Sawada K, Kobayashi M, et al. Exosomal CD47 plays an essential role in immune evasion in ovarian cancer. Mol Cancer Res. 2021;19(9):1583\u201395. https:\/\/doi.org\/10.1158\/1541-7786.MCR-20-0956.","journal-title":"Mol Cancer Res"},{"issue":"24","key":"991_CR72","doi-asserted-by":"publisher","first-page":"39021","DOI":"10.18632\/oncotarget.16547","volume":"8","author":"R Liu","year":"2017","unstructured":"Liu R, Wei H, Gao P, et al. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis. Oncotarget. 2017;8(24):39021\u201332. https:\/\/doi.org\/10.18632\/oncotarget.16547.","journal-title":"Oncotarget"},{"key":"991_CR73","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.omto.2021.01.002","volume":"20","author":"R Shu","year":"2021","unstructured":"Shu R, Evtimov VJ, Hammett MV, et al. Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer. Molecul Ther Oncolytics. 2021;20:325\u201341. https:\/\/doi.org\/10.1016\/j.omto.2021.01.002.","journal-title":"Molecul Ther Oncolytics"},{"issue":"12","key":"991_CR74","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.cellsig.2006.05.019","volume":"18","author":"Q Meng","year":"2006","unstructured":"Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal. 2006;18(12):2262\u201371. https:\/\/doi.org\/10.1016\/j.cellsig.2006.05.019.","journal-title":"Cell Signal"},{"issue":"7","key":"991_CR75","first-page":"4077","volume":"11","author":"H Li","year":"2019","unstructured":"Li H, Zhang Q, Wu Q, et al. Interleukin-22 secreted by cancer-associated fibroblasts regulates the proliferation and metastasis of lung cancer cells via the PI3K-Akt-mTOR signaling pathway. Am J Transl Res. 2019;11(7):4077\u201388.","journal-title":"Am J Transl Res"},{"key":"991_CR76","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.canlet.2019.12.039","volume":"473","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Zhou Q, Wu X, et al. VCAM-1 secreted from cancer-associated fibroblasts enhances the growth and invasion of lung cancer cells through AKT and MAPK signaling. Cancer Lett. 2020;473:62\u201373. https:\/\/doi.org\/10.1016\/j.canlet.2019.12.039.","journal-title":"Cancer Lett"},{"issue":"6","key":"991_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129593","volume":"10","author":"L Ying","year":"2015","unstructured":"Ying L, Zhu Z, Xu Z, et al. Cancer associated fibroblast-derived hepatocyte growth factor inhibits the paclitaxel-induced apoptosis of lung cancer A549 cells by up-regulating the PI3K\/Akt and GRP78 signaling on a microfluidic platform. PLoS ONE. 2015;10(6): e0129593. https:\/\/doi.org\/10.1371\/journal.pone.0129593.","journal-title":"PLoS ONE"},{"issue":"1","key":"991_CR78","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12964-019-0432-5","volume":"17","author":"J Ma","year":"2019","unstructured":"Ma J, Sun X, Wang Y, Chen B, Qian L, Wang Y. Fibroblast-derived CXCL12 regulates PTEN expression and is associated with the proliferation and invasion of colon cancer cells via PI3k\/Akt signaling. Cell Commun Signal. 2019;17(1):119. https:\/\/doi.org\/10.1186\/s12964-019-0432-5.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"991_CR79","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/cbf.3446","volume":"38","author":"T Pang","year":"2020","unstructured":"Pang T, Yin X, Luo T, et al. Cancer-associated fibroblasts promote malignancy of gastric cancer cells via nodal signalling. Cell Biochem Funct. 2020;38(1):4\u201311. https:\/\/doi.org\/10.1002\/cbf.3446.","journal-title":"Cell Biochem Funct"},{"key":"991_CR80","doi-asserted-by":"publisher","unstructured":"Li Y yin, Tao Y wei, Gao S, et al. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p. EBioMedicine. 2018;36:209\u2013220 https:\/\/doi.org\/10.1016\/j.ebiom.2018.09.006","DOI":"10.1016\/j.ebiom.2018.09.006"},{"issue":"7","key":"991_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068923","volume":"8","author":"KS Subramaniam","year":"2013","unstructured":"Subramaniam KS, Tham ST, Mohamed Z, Woo YL, Mat Adenan NA, Chung I. Cancer-associated fibroblasts promote proliferation of endometrial cancer cells. PLoS ONE. 2013;8(7): e68923. https:\/\/doi.org\/10.1371\/journal.pone.0068923.","journal-title":"PLoS ONE"},{"issue":"7","key":"991_CR82","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/ijc.32178","volume":"145","author":"W Cacheux","year":"2019","unstructured":"Cacheux W, Li\u00e8vre A, Richon S, et al. Interaction between IGF2-PI3K axis and cancer-associated-fibroblasts promotes anal squamous carcinogenesis. Int J Cancer. 2019;145(7):1852\u20139. https:\/\/doi.org\/10.1002\/ijc.32178.","journal-title":"Int J Cancer"},{"key":"991_CR83","doi-asserted-by":"publisher","first-page":"153303382097753","DOI":"10.1177\/1533033820977535","volume":"19","author":"L Chu","year":"2020","unstructured":"Chu L, Wang F, Zhang W, Li HF, Xu J, Tong XW. Periostin secreted by carcinoma-associated fibroblasts promotes ovarian cancer cell platinum resistance through the PI3K\/Akt signaling pathway. Technol Cancer Res Treat. 2020;19:1533033820977535. https:\/\/doi.org\/10.1177\/1533033820977535.","journal-title":"Technol Cancer Res Treat"},{"issue":"1","key":"991_CR84","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1186\/s12885-019-5824-9","volume":"19","author":"J Deng","year":"2019","unstructured":"Deng J, Bai X, Feng X, et al. Inhibition of PI3K\/Akt\/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. BMC Cancer. 2019;19(1):618. https:\/\/doi.org\/10.1186\/s12885-019-5824-9.","journal-title":"BMC Cancer"},{"issue":"6","key":"991_CR85","first-page":"2590","volume":"11","author":"B Lawal","year":"2021","unstructured":"Lawal B, Lo WC, Mokgautsi N, et al. A preclinical report of a cobimetinib-inspired novel anticancer small-molecule scaffold of isoflavones, NSC777213, for targeting PI3K\/AKT\/mTOR\/MEK in multiple cancers. Am J Cancer Res. 2021;11(6):2590\u2013617.","journal-title":"Am J Cancer Res"},{"issue":"8","key":"991_CR86","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/1878-0261.12888","volume":"15","author":"F Fabi","year":"2021","unstructured":"Fabi F, Adam P, Parent S, Tardif L, Cadrin M, Asselin E. Pharmacologic inhibition of Akt in combination with chemotherapeutic agents effectively induces apoptosis in ovarian and endometrial cancer cell lines. Mol Oncol. 2021;15(8):2106\u201319. https:\/\/doi.org\/10.1002\/1878-0261.12888.","journal-title":"Mol Oncol"},{"issue":"3","key":"991_CR87","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/annonc\/mdw672","volume":"28","author":"UA Matulonis","year":"2017","unstructured":"Matulonis UA, Wulf GM, Barry WT, et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017;28(3):512\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdw672.","journal-title":"Ann Oncol"},{"issue":"12","key":"991_CR88","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41419-021-04429-6","volume":"12","author":"G Qi","year":"2021","unstructured":"Qi G, Ma H, Li Y, Peng J, Chen J, Kong B. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR\/autophagy pathway. Cell Death Dis. 2021;12(12):1135. https:\/\/doi.org\/10.1038\/s41419-021-04429-6.","journal-title":"Cell Death Dis"},{"issue":"9","key":"991_CR89","first-page":"3817","volume":"32","author":"CV Madsen","year":"2012","unstructured":"Madsen CV, Steffensen KD, Olsen DA, et al. Serum platelet-derived growth factor and fibroblast growth factor in patients with benign and malignant ovarian tumors. Anticancer Res. 2012;32(9):3817\u201325.","journal-title":"Anticancer Res"},{"issue":"6","key":"991_CR90","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.3892\/ijmm.2019.4361","volume":"44","author":"Q Han","year":"2019","unstructured":"Han Q, Huang B, Huang Z, et al. Tumor cell-fibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer. Int J Mol Med. 2019;44(6):2245\u201355. https:\/\/doi.org\/10.3892\/ijmm.2019.4361.","journal-title":"Int J Mol Med"},{"key":"991_CR91","doi-asserted-by":"publisher","unstructured":"Salgado-Albarr\u00e1n M, Sp\u00e4th J, Gonz\u00e1lez-Barrios R, Baumbach J, Soto-Reyes E. CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy. npj Syst Biol Appl. 2022;8(1): 5 https:\/\/doi.org\/10.1038\/s41540-022-00214-z","DOI":"10.1038\/s41540-022-00214-z"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-022-00991-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-022-00991-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-022-00991-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T19:50:38Z","timestamp":1691697038000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-022-00991-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["991"],"URL":"https:\/\/doi.org\/10.1186\/s12964-022-00991-4","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"27 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the Region of Southern Denmark (S-20190102) and The Danish Data Protection Agency (Case No. 19\/37168) approved the study. All patients signed a written informed consent before sample collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"176"}}